Balversa 4 MG
Ended Awarded
- Contract number
- 36C24525N1036
- Awardee
-
Janssen Biotech Inc. UEI NVYMGFA53MN7
- Awarding agency
-
Veterans Integrated Service Network 5
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $18,804
Award facts
- Contract value 100% obligated
- $18,803.91 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Carrollton, TX 75010, USA
Award details come from SAM.gov/FPDS.
About this award
Janssen Biotech Inc., a Johnson & Johnson subsidiary operating as Centocor Ortho Biotech Inc., was awarded a delivery order valued at $18,803.91 for BALVERSA 4 MG (erdafitinib), an oncology medication, by Veterans Integrated Service Network 5 (VISN 5) under the Department of Veterans Affairs. The firm fixed-price delivery order was awarded on September 25, 2025, with an ultimate completion date of September 29, 2025, and will be performed in Carrollton, Texas. This award carries no set-aside designation and is issued under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB).
This delivery order is issued against Janssen Biotech's existing single-award Blanket Purchase Agreement with the VA valued at $15 million through September 19, 2026, which is specifically designed to provide oncology medications including BALVERSA and CARVYKTI to support comprehensive healthcare services for veterans. The company also holds a multiple-award Federal Supply Schedule contract for Pharmaceuticals and Drugs valued at $6.8 billion, enabling the VA and its Veterans Integrated Service Networks to efficiently procure specialty medical products. Through these vehicles, Janssen Biotech serves as a critical supplier of advanced oncology medications to veteran healthcare programs across multiple VISNs nationwide.
Quick answers
Who was awarded contract 36C24525N1036?
36C24525N1036 was awarded to Janssen Biotech Inc. by Veterans Integrated Service Network 5 (Veterans Health Administration) on September 25, 2025.
How much is contract 36C24525N1036 worth?
The government has obligated $18,804 on 36C24525N1036.
Is contract 36C24525N1036 an order under another contract?
Yes. 36C24525N1036 is a delivery order under 36F79724D0176, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C24525N1036 competed?
The extent of competition for 36C24525N1036 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award